Literature DB >> 16081789

Prolongation of sheep corneal allograft survival by transfer of the gene encoding ovine IL-12-p40 but not IL-4 to donor corneal endothelium.

Sonja Klebe1, Douglas J Coster, Pamela J Sykes, Sarah Swinburne, Peter Hallsworth, Jean-Pierre Y Scheerlinck, Ravi Krishnan, Keryn A Williams.   

Abstract

Immunological rejection is the major cause of human corneal allograft failure. We hypothesized that local production of IL-4 or the p40 subunit of IL-12 (p40 IL-12) by the grafted cornea might prolong allograft survival. Replication-deficient adenoviral vectors encoding ovine IL-4 or p40 IL-12 and GFP were generated and used to infect ovine corneas ex vivo. mRNA for each cytokine was detected in infected corneas, and the presence of secreted protein in corneal supernatants was confirmed by bioassay (for IL-4) or immunoprecipitation (for p40 IL-12). Sheep received uninfected or gene-modified orthotopic corneal allografts. Postoperatively, untreated corneas (n = 13) and corneas expressing GFP (n = 6) were rejected at a median of 21 and 20 days, respectively. Corneas expressing IL-4 (n = 6) underwent rejection at 18.5 days (p > 0.05 compared with controls) and histology demonstrated the presence of eosinophils. In contrast, corneas expressing p40 IL-12 (n = 9) showed prolonged allograft survival (median day to rejection = 45 days, p = 0.003). Local intraocular production of p40 IL-12 thus prolonged corneal graft survival significantly, but local production of the prototypic immunomodulatory cytokine IL-4 induced eosinophilia, inflammation, and rejection. These findings have important implications for the development of novel strategies to improve human corneal graft survival.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16081789     DOI: 10.4049/jimmunol.175.4.2219

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  7 in total

Review 1.  Immune privilege of corneal allografts.

Authors:  Jerry Y Niederkorn; D Frank P Larkin
Journal:  Ocul Immunol Inflamm       Date:  2010-06       Impact factor: 3.070

Review 2.  Gene therapy in corneal transplantation.

Authors:  Yureeda Qazi; Pedram Hamrah
Journal:  Semin Ophthalmol       Date:  2013 Sep-Nov       Impact factor: 1.975

Review 3.  Gene Therapy in the Anterior Eye Segment.

Authors:  Cynthia Amador; Ruchi Shah; Sean Ghiam; Andrei A Kramerov; Alexander V Ljubimov
Journal:  Curr Gene Ther       Date:  2022       Impact factor: 4.391

4.  The Balance of Th1/Th2 and LAP+Tregs/Th17 Cells Is Crucial for Graft Survival in Allogeneic Corneal Transplantation.

Authors:  Shang Li; Jing Yu; Chungang Guo; Ying Jie; Zhiqiang Pan
Journal:  J Ophthalmol       Date:  2018-02-08       Impact factor: 1.909

Review 5.  Lentiviral Vectors for Ocular Gene Therapy.

Authors:  Yvan Arsenijevic; Adeline Berger; Florian Udry; Corinne Kostic
Journal:  Pharmaceutics       Date:  2022-07-31       Impact factor: 6.525

Review 6.  Strategies for local gene therapy of corneal allograft rejection.

Authors:  Pho Nguyen; Samuel C Yiu
Journal:  Middle East Afr J Ophthalmol       Date:  2013 Jan-Mar

7.  Effects of an intravitreal injection of interleukin-35-expressing plasmid on pro-inflammatory and anti-inflammatory cytokines.

Authors:  Chao Hou; Qianni Wu; Chen Ouyang; Ting Huang
Journal:  Int J Mol Med       Date:  2016-07-22       Impact factor: 4.101

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.